Targeting PDE4 has been validated as an effective therapeutic strategy for inflammatory conditions, including chronic obstructive pulmonary disease (COPD), inflammatory bowel diseases (IBD), rheumatic arthritis (RA), atopic dermatitis (AD), asthma, psoriasis, and lupus [14,15]. The gene discussed is PDE4A; the disease is inflammatory bowel disease.